{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \\<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 h.","groups":[{"description":"Participants with RRMM received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles.","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8mg OX40"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion as powder for solution Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin EOI on day 1 of 21-day cycles.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8mg OX40"}],"paramType":"NUMBER","populationDescription":"Safety Population included all participants who received at least 1 dose of any component of the combination therapy.","reportingStatus":"POSTED","timeFrame":"Up to 170 weeks","title":"DE Phase: Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}